5 November 2026

Germany in the crosshairs: The latest on MFN pricing

Health Data and StatisticsIndication-Based PricingValue-Based Pricing
Graphic for article: 'Germany in the crosshairs: the latest on MFN pricing' with two circular headshots (Graham Cookson and Grace Hampson) on a purple background.

Germany is an important player in the life sciences and pharmaceutical industry. How is MFN playing out there?

In this bonus episode, Grace Hampson is joined by Graham Cookson, Chief Executive of OHE, to explore the most recent developments in US ‘Most-Favoured Nation’ (MFN) pricing.

They’ll discuss

  • US pressure on Germany through a Section 301 investigation.
  • What two recently published pharmaceutical company deals with the US government reveal about the policy’s aims.
  • How Europe and the rest of the world might respond

Speakers

Listen to the episode

If you enjoy this discussion, look out for a special episode of A Dose of Economics coming soon. We will be asking experts at the upcoming ISPOR Europe 2026 for their take on ‘Most Favoured Nation’ pricing, and what it means for patients, payers and the pharma industry in markets around the world. 

Never miss an episode

You may also be interested in

Purple banner with two circular headshots (Neil Grubert and Amanda Cole) and the article title about Most Favored Nation pricing on policy, patients, and pharma.

Most Favored Nation pricing: what it means for policy, patients and pharma 

Desert landscape with three massive red sandstone buttes rising from a rocky plain under a blue sky with scattered clouds, a dirt road winding toward them at center.

Global equity in the shadow of US pricing reform: Access by bargaining power? | World Health Summit 2026

Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate

Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order